Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03131037 | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | PHASE1 | COMPLETED | 12 | — | — | May 4, 2017 | Sep 20, 2023 | Jul 11, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Study Arm | EXPERIMENTAL | CAN-2409 + valacyclovir |
| Name | Type | Description |
|---|---|---|
| CAN-2409 + valacyclovir | BIOLOGICAL | CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection. |
Inclusion Criteria: * Pathologically documented non-small cell carcinoma (cytology or histology) that is accessible via standard-of-care staging procedures: (1) EBUS or (2) surgical approaches (eg mediastinoscopy, mediastinotomy or VATS). * Resectable with negative lymph nodes based on imaging with...